The microglial phagocytic role with specific plaque types in the Alzheimer disease brain

Michael R D'Andrea1, Gregory M Cole, March D Ard

  • 1Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, D404, Spring House, PA 19477, USA. mdandrea@prdus.jnj.com

Insights

Microglia in Alzheimer disease (AD) brains are phagocytic cells that react to specific amyloid plaque formations. This review supports their role in clearing plaques, not forming them.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer disease (AD) is characterized by glial inflammation and amyloid plaques.
  • The precise role of microglia in AD pathogenesis, specifically whether they form or clear amyloid plaques, remains debated.
  • Understanding microglial interaction with different amyloid plaque types is crucial.

Purpose of the Study:

  • To present evidence supporting the phagocytic role of microglia in the AD brain.
  • To elucidate the reasons behind microglial association with specific amyloid plaque types.
  • To clarify the temporal relationship between microglial activation and amyloid plaque formation.

Main Methods:

  • Review of existing literature and experimental data on microglial function in AD.
  • Analysis of evidence for microglial phagocytosis of amyloid fibrils.
  • Examination of factors influencing microglial-plaque interactions and specific plaque morphologies.

Main Results:

  • Substantial evidence supports microglia acting as phagocytic cells in the AD brain.
  • Microglial association with certain plaque types can be explained by their formation mechanisms.
  • Microglial activation is predominantly a response subsequent to specific amyloid plaque formations.

Conclusions:

  • Microglia play a reactive, phagocytic role in Alzheimer disease, clearing amyloid plaques.
  • The specific interaction patterns between microglia and amyloid plaques are linked to plaque formation processes.
  • Microglial activation is a downstream event in the cascade of Alzheimer disease pathology.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...